Clinical trials: Alzheimer; Early Onset
Alzheimer Disease, Early Onset, Cognitive Impairment
Hyperspectral Retinal Observations for the Cross-sectional Detection of Alzheimer's Disease
Two devices will be tested in this research: 1. Mantis Photonics' hyperspectral camera for non-invasive retinal examination (i.e., a hardware medical device under investigation). 2.
- Conditions
- Alzheimer Disease, Early Onset, Cognitive Impairment, Cognitive Decline
- Trial name
- NCT05604183
- Testing
- non-invasive hyperspectral retinoscopy, blood sample, Test of cognitive ability on tablet computer with CoGNIT software
- Where
- 2 sites in Sweden
- Volunteers
- 80 people
- Sponsor
- Mantis Photonics AB
Alzheimer Disease, Alzheimer Disease, Early Onset
Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy
Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits amyloid and tau) in the brain, and changes in the gamma frequency band on EEG.
- Conditions
- Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer's Disease (Incl Subtypes)
- Trial name
- NCT05655195
- Testing
- GENUS device (Active Settings)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Massachusetts Institute of Technology
Alzheimer Disease, Early Onset
A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease
This study is a multicenter, randomized, double-blinded, placebo-controlled Phase 3 study comparing LIPUS-Brain transcranial low-intensity pulsed-wave ultrasound device to placebo in patients with Early Alzheimer's Disease.
- Trial name
- NCT05983575
- Testing
- LIPUS-Brain
- Where
- 19 sites in Japan
- Volunteers
- 220 people
- Sponsor
- Sound Wave Innovation CO., LTD.
Alzheimer Disease, Early Onset
Adapted Home-based Exercise Program "T&E" (Test-and-Exercise) in Persons With Alzheimer's Disease (HOPE Trial)
The aim of this exploratory pilot study is to assess the feasibility and effectiveness of the adapted T\&E home-based exercise program on the basic functional mobility and executive functions in persons with mild or probable…
- Trial name
- HOPE (NCT04916964)
- Testing
- Test and exercise home-based program
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- HES-SO Valais-Wallis
Alzheimer Disease, Early Onset
The Effect of Black Mulberry (Morus Nigra) Consumption on Cognitive Functions
The study was conducted with 44 patients who were diagnosed with mild-to-moderate Alzheimer's Disease. Participants were divided into 2 groups intervention group and the control group.
- Trial name
- NCT05406648
- Testing
- Morus nigra concentrate
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people
- Sponsor
- Hacettepe University
Alzheimer Disease, Early Onset, MCI
The Interactive Physical and Cognitive Exercise System
This study is intended to clarify the benefits to brain health and thinking processes that result from different forms of exercise.
- Conditions
- Alzheimer Disease, Early Onset, MCI, Aging, Mild Cognitive Impairment
- Trial name
- iPACES™ (NCT03069391)
- Testing
- physical exercise alone (PES) first, cognitive exercise alone (iCE) first, interactive Physical and Cognitive Exercise (iPACES™)
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Union College, New York
Alzheimer Disease, Early Onset
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind, multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL628 in participants…
- Trial name
- NCT07328451
- Testing
- DNL628
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 68 people
- Sponsor
- Denali Therapeutics Inc.
Alzheimer Disease, Early Onset
Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau
The primary purpose of this phase 1b study is to further assess the safety and reversibility of focused ultrasound induced blood-brain barrier opening (FUS-BBBO) in participants with Alzheimer´s Disease (AD) using a…
- Trial name
- FUS-AD (NCT06600880)
- Testing
- Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Alzheimer's Disease, Early Onset, Logopenic Progressive Aphasia
Tau Imaging in Young Onset Dementia
The central goal of this study is to determine and compare the similarities and differences in regional brain uptake of [18F]T807 in patients with typical Alzheimer's Disease (AD), Posterior Cortical Atrophy (PCA), and Logopenic…
- Conditions
- Alzheimer's Disease, Early Onset, Logopenic Progressive Aphasia, Posterior Cortical Atrophy (PCA)
- Trial name
- NCT02289118
- Testing
- [18F]-T807 imaging tracer
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Pennsylvania
Alzheimer's Disease
Early-onset and Late-onset Sporadic Alzheimer's Disease (AD)
Alzheimer's disease (AD) is usually associated with aging, age being the principal identified risk factor. However, younger subjects also develop AD and the prevalence of early onset AD is unknown.
- Trial name
- NCT00987090
- Testing
- Clinic and neuropsychologic evaluation, MRI, PET
- Where
- France
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Alzheimer Disease, Early Onset
Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease
multi-center, randomized, double-blind, parallel-group,placebo-controlled study to evaluate the safety and tolerability, efficacy, and PK of 60 mg AD-35 administered QD during 6 months of double-blind treatment followed by a…
- Trial name
- ROAD (NCT03625401)
- Testing
- AD-35 60mg group
- Where
- 10 sites in United States
- Volunteers
- 55 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Alzheimer Disease, Alzheimer Disease 1
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Alzheimer's disease.
- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- NCT04100889
- Testing
- No Intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Early Onset Alzheimer Disease, Alzheimer Disease
Longitudinal Early-onset Alzheimer's Disease Study Protocol
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment.
- Conditions
- Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- LEADS (NCT03507257)
- Testing
- Flortaucipir, Florbetaben, Fluorodeoxyglucose
- Where
- 23 sites in United States, Argentina and 4 more
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- Indiana University
Alzheimer Disease, Early Onset
Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease
The objective of the study is to evaluate the ability of (-)-L-2',3'-dideoxy-3'-thiacytidine (3TC) to engage its intended target, penetrate the central nervous system (CNS), suppress neurodegeneration, and assess safety and…
- Trial name
- ART-AD (NCT04552795)
- Testing
- 3TC
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Alzheimer Disease, Early Onset
Theta-burst Stimulation on Cognitive Function in the Patients With Young-onset Alzheimer's Disease Dementia
Young-onset dementia (YOD) is a devastating condition, and it produces substantial psychosocial impacts on individual's functioning and family's care burden. Alzheimer's disease (AD) dementia is the most common type in YOD.
- Trial name
- NCT04042532
- Testing
- Theta-burst stimulation (TBS)
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Alzheimer Disease
Early Onset Alzheimer's Disease Genomic Study
The purpose of this study is to collect samples from patients with Early-Onset Alzheimer's disease (AD) and their immediate family members for molecular analysis.
- Trial name
- TGen (NCT03645993)
- Testing
- Genetic Testing
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Baylor Research Institute
Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD
This is a randomized, double-blind clinical trial of a daily oral dose of 200 mg emtricitabine vs. placebo in 35 participants with biomarker-confirmed MCI or mild to moderate dementia due to Alzheimer's disease.
- Conditions
- Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Moderate Dementia
- Trial name
- LINE-AD (NCT04500847)
- Testing
- Emtriva Capsule
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Butler Hospital
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC
Early Onset Alzheimer Disease, Alzheimer Disease
Sleep Apnea in Early to Mid-Stage Alzheimer's Disease
Obstructive sleep apnea (OSA) is much more common in the elderly than in the young; the latest studies show prevalence between 45% and 62% in individuals over 60.
- Conditions
- Early Onset Alzheimer Disease, Alzheimer Disease, Obstructive Sleep Apnea Syndromes
- Trial name
- AZAP (NCT01400542)
- Testing
- CPAP Treatment, No treatment
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Effects of Mitochondrial-targeted Antioxidant on Mild Cognitive Impairment (MCI) Patients
Neurodegenerative diseases such as Mild Cognitive Impairment, Alzheimer's, and dementia affect millions of Americans. Although these diseases are heavily researched, there is very little research examining the impact of…
- Trial name
- NCT03514875
- Testing
- MitoQ
- Sponsor
- University of Nebraska